Anthrax vaccine powder formulations for nasal mucosal delivery

Anthrax remains a serious threat worldwide as a bioterror agent. A second-generation anthrax vaccine currently under clinical evaluation consists of a recombinant Protective Antigen (rPA) of Bacillus anthracis. We have previously demonstrated that complete protection against inhalational anthrax can...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of pharmaceutical sciences 2006-01, Vol.95 (1), p.80-96
Hauptverfasser:	Jiang, Ge, Joshi, Sangeeta B., Peek, Laura J., Brandau, Duane T., Huang, Juan, Ferriter, Matthew S., Woodley, Wendy D., Ford, Brandi M., Mar, Kevin D., Mikszta, John A., Hwang, C.Robin, Ulrich, Robert, Harvey, Noel G., Middaugh, C.Russell, Sullivan, Vincent J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intranasal anthrax Anthrax Vaccines - chemistry Antigens, Bacterial - immunology Bacillus anthracis - immunology Biological and medical sciences Chemistry, Pharmaceutical Drug Compounding Drug Stability Freeze Drying General pharmacology Medical sciences nasal Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments powder formulation Powders recombinant protective antigen stability
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!